Myeloma

The Food and Drug Administration has granted an accelerated approval to Xpovio in combination with dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received more than four prior therapies.

The FDA has approved the combination of Darzalex with Revlimid and dexamethasone (DRd) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

The Food and Drug Administration lifted a partial clinical hold on the CANOVA trial, examining Venclexta plus dexamethasone for some patients with relapsed/refractory myeloma.

In the second part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him about the past, present and future of the myeloma landscape.

In the first part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him on the current initiatives and resources available to patients.

Researchers determined that having difficulty performing at least one instrumental activity of daily living puts older patients at risk of death, unplanned hospitalization and emergency department visits.

The Food and Drug Administration granted a priority review to Darzalex in combination with Velcade (bortezomib), thalidomide and dexamethasone, also known as Vtd, for the front-line treatment of newly diagnosed patients with multiple myeloma.

The FDA has approved Jakafi, the first and only treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients aged 12 years and older.

From World Blood Cancer Day to today’s top performers fundraising for lifesaving research, here’s what’s making headlines in the cancer space this week.

Using Revlimid as a preventative treatment for smoldering multiple myeloma significantly reduced the risk for the precursor disease to progress into cancer, compared with just observation.

Treatment with bb2121 showed promising efficacy and safety among heavily pretreated patients with multiple myeloma, according to interim results published in the New England Journal of Medicine.

Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.

An expert discusses how CAR-T cells will fit into the treatment paradigm for patients with multiple myeloma in the future.

Although a reasonable and often curative treatment option, use of allogeneic hematopoietic stem cell therapy in relapsed multiple myeloma still tends to fall under the radar.

An expert discusses treating multiple myeloma with potential curative intent.

The Oncologic Drugs Advisory Committee (ODAC) voted 8 to 5 recommending the FDA delay approval of selinexor for the treatment of patients with penta-refractory multiple myeloma until further trial data are available.

Outcomes associated with subcutaneous injections of Darzalex (daratumumab) appeared similar to IV administration in patients with relapsed or refractory myeloma, according to the phase 3 COLUMBA trial.

Patients with multiple myeloma find relief from side effects, thanks to newer drug combinations.

Researchers are using innovative technology to hunt down hidden cancer cells.

The Food and Drug Administration (FDA) approved a split-dosing regimen for Darzalex (daratumumab) for the treatment of patients with multiple myeloma.

Obesity may be to blame for increasing rates of certain cancers in young adults.

Splitting up Darzalex dosing had comparable results to standard dosing schedules in patients with myeloma.

From World Cancer Day to top performers and athletes, here is a quick overview of what is making headlines in the cancer space.

Multiple myeloma is a type of blood cancer that originates in the bones. Here’s what you need to know about the disease.

All in all, I’m very pleased with being able to get my oral chemo directly from my clinic’s pharmacy. The staff knows me and they know my doctor.

Toronto’s Jeff Lipton, PhD, MD, FRCPC, shares his thoughts on the outlook for blood cancers.

In an interview with CURE, Filippo Milano, M.D., Ph.D., explains what cord blood transplantation is and why it is important for patients to learn more.

Patients with myeloma who took higher doses of Kyprolis plus dexamethasone tended to have better survival outcomes, according to a recent study.

The combination of Darzalex (daratumumab), Revlimid (lenalidomide) and dexamethasone significantly reduced the risk for disease progression in patients with newly diagnosed multiple myeloma.

New findings could spark change in the way that some patients with multiple myeloma are treated.